Thursday, 06 September 2012
Meda has signed an agreement with the U.S. company, Jazz
Pharmaceuticals to acquire a portfolio of 6 pharmaceutical products
focused on Women’s Health.
The largest and most important product is Elestrin, a patented product
with sales of almost 100 MSEK. Elestrin is indicated for the treatment
of moderate-to-severe vasomotor symptoms (i.e. hot flashes) associated
with menopause. Since the launch in 2007, Elestrin has become a leading
brand in the topical ERT (estrogen replacement therapy) market.
Together with Meda’s present portfolio of products in the therapy area
of Women`s Health the sales will be over 500 MSEK.
“We can now strengthen the product offering in the U.S. as well as
expand our sales force with people that have good experience and
excellent track-record", said Anders Lönner, CEO of Meda AB. "Meda has
already a presence in the Women’s Health area and this deal will create
positive marketing synergies”.
The closing of the acquisition is subject to the satisfaction of
customary closing conditions and regulatory approvals, including
antitrust approvals. With an anticipated closing of the acquisition
during the 4th quarter this year, the effect on Meda’s earnings per
share is expected to be accretive already during 2013. Meda’s existing
credit facilities will finance the acquisition.
Based on a press release